Pfizer (PFE) : Dimensional Fund Advisors Lp reduced its stake in Pfizer by 4.76% during the most recent quarter end. The investment management company now holds a total of 40,688,910 shares of Pfizer which is valued at $1,421,263,626 after selling 2,032,667 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Pfizer makes up approximately 0.78% of Dimensional Fund Advisors Lp’s portfolio.
Other Hedge Funds, Including , Denver Investment Advisors reduced its stake in PFE by selling 32,033 shares or 6.36% in the most recent quarter. The Hedge Fund company now holds 471,943 shares of PFE which is valued at $16,588,796. Pfizer makes up approx 0.71% of Denver Investment Advisors’s portfolio.Shinko Asset Management Ltd. reduced its stake in PFE by selling 354 shares or 2.19% in the most recent quarter. The Hedge Fund company now holds 15,798 shares of PFE which is valued at $580,419.
Pfizer opened for trading at $34.75 and hit $35.15 on the upside on Wednesday, eventually ending the session at $35.14, with a gain of 1.01% or 0.35 points. The heightened volatility saw the trading volume jump to 1,70,40,893 shares. Company has a market cap of $213,147 M.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.